About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

THERANEXUS, BBDF and Cardiff University present their novel research on Batten-1 and Batten disease at Worldsymposium 2023

20/02/2023 6PM CET

Download PDF File (<1Mo)

AISTROSIGHT: New joint project team between Theranexus, INRIA, Claude Bernard University Lyon 1 and Hospices Civils de Lyon targeting rare neurological diseases

10/02/2023 before market opens

Download PDF File (<1Mo)

THERANEXUS publishes its cash position as of 31 December 2022 and announces organizational changes

18/01/2023 before market opens

Download PDF File (<1Mo)

New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)

05/01/2023

Download PDF File (<1Mo)

THERANEXUS announces participation in the 41STannual J.P. Morgan Healthcare Conference January 9-12, 2023 in San Francisco

20/12/2022

Download PDF File (<1Mo)